Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy - Wikidata - wikimedia - TriplyDB

Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy

Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy

http://www.wikidata.org/entity/Q36642014

about

Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice Diagnosis, prognosis, and management of cryptogenic stroke Brain-heart axis--Review Article Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation Cardioembolic Stroke.Stroke Risk Factors, Genetics, and Prevention.Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study.N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort Cryptogenic stroke: A diagnostic challenge Isolated insular strokes and plasma MR-proANP levels are associated with newly diagnosed atrial fibrillation: a pilot study.Association between left atrial abnormality on ECG and vascular brain injury on MRI in the Cardiovascular Health Study Left atrial enlargement and stroke recurrence: the Northern Manhattan Stroke Study Cardiac magnetic resonance imaging: a new tool to identify cardioaortic sources in ischaemic stroke.Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.Left Atrial Appendage Function and Stroke Risk Atrial Cardiopathy and Cryptogenic Stroke: A Cross-sectional Pilot Study.Advances in stroke prevention.N-Terminal Pro-B-Type Natriuretic Peptide and Risk of Future Cognitive Impairment in the REGARDS Cohort.Atrial cardiopathy: a mechanism of cryptogenic stroke.Adiponectin, cardiovascular disease, and mortality: parsing the dual prognostic implications of a complex adipokine.Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study).Complex Left Atrial Appendage Morphology Is an Independent Risk Factor for Cryptogenic Ischemic Stroke

P2860

Q26752352-A1B9ED7B-5A45-4363-AF5A-B11CCFA774B5 Q26766106-DB56E41B-ACD9-48D6-8C82-E0C0A79EA39B Q26782446-661A130A-1BC7-4B05-94C3-43D217C9B531 Q28084658-12A38D40-A6D7-4108-9AF0-6AC54EF5D445 Q30238631-393A4D55-F35E-412A-8AB3-41F6A1407AFD Q30238633-9D218F53-F7CE-4379-AFDF-C064B1C467CE Q30663685-B5A2C9D5-F4C0-4F66-A763-8FDFDAC75FFE Q33848664-9B388362-A8E7-4293-94B2-792205BA49E0 Q34080669-D09BA124-7DF1-47D8-8F7D-3BCF3553D94B Q34335867-2379332D-490E-44BB-9F0E-9D57A4D40508 Q35125407-5327FE98-AB02-4B69-95DB-688B1D643E7B Q35126055-C2AD2482-41A3-4C23-B9FF-3FFF9AA988A8 Q35639757-4991BE1A-4C6C-4A7A-80DF-8894042C2E77 Q36142058-01C3616A-7A37-4FB5-AF02-C99E52BB2E50 Q36155695-99DC8639-2BDA-40A1-B72A-262BAC44A8E8 Q36319590-0C9D48DC-1BC4-4B2D-BE6C-3128ED700295 Q36414754-448B85A0-FFEA-4330-A113-35CD1CFABBEB Q38380852-DC22EEBF-5220-49CF-8779-705BAA142772 Q38388347-DF070F71-528E-4ED1-A6FC-8F39886E69B9 Q38656036-AFB86D5D-C24F-46AE-89A6-4FE24AC4E3E5 Q42908938-42E580D8-647F-4F6C-9ED3-A2056446A1D7 Q52657350-8776E025-2237-4328-A62A-CAF62F0505D9 Q59136305-8D318968-8E53-4061-B6D2-9F016894AA34

P2860

Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy

http://www.wikidata.org/entity/Q36642014

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Amino terminal pro-B-type natr ...... oice of antithrombotic therapy

@ast

Amino terminal pro-B-type natr ...... oice of antithrombotic therapy

@en

type

label

Amino terminal pro-B-type natr ...... oice of antithrombotic therapy

@ast

Amino terminal pro-B-type natr ...... oice of antithrombotic therapy

@en

prefLabel

Amino terminal pro-B-type natr ...... oice of antithrombotic therapy

@ast

Amino terminal pro-B-type natr ...... oice of antithrombotic therapy

@en

P1433

Q36642014-54174177-7C0D-4D00-95DD-9C97535000AA

P1476

Q36642014-C7C21530-94B6-46D0-A95A-82FFF5DD32E3

P2093

Q36642014-0BD0F92F-6282-4E3F-A1D4-3433A217CE1C

Q36642014-2951D5EB-8F66-4AF9-B082-17D1B08DA385

Q36642014-4851DAB1-2A1D-4ADB-BA36-B2693BD7567D

Q36642014-655D7D26-6D4F-48C5-B9FE-62008FBC7846

Q36642014-7B17D844-1723-4117-BF54-11CF481403FC

Q36642014-8A4FAEA3-828C-44D0-99F1-DCE285CF47AD

Q36642014-A7098176-41E3-4E2B-8A6A-93FC5F2D9A48

Q36642014-BECDFF14-0E70-408D-B00E-A05A5FBF4D47

Q36642014-D60D5221-5C85-4F30-A5DB-CE19D7C65BF7

Q36642014-D69FA1CA-F029-478B-88F4-3577AEE68773

P2860

Q36642014-005FA9BF-4E3A-45FF-A593-E20192D9EE01

Q36642014-12D8EA6F-382A-49C8-B671-3F1C6EB50EC7

Q36642014-21D40468-7694-4B8A-A44B-46253E3C1D9A

Q36642014-22DCD86E-679B-4D78-B434-33CE1A8840CB

Q36642014-3FD3D302-EB24-4950-BD36-DBAA08A98F50

Q36642014-4206E23B-2F19-43D5-BCE9-D462117D7C65

Q36642014-50F2D874-6D7A-4BBC-ADD6-4B31EBB96255

Q36642014-589116A5-FAB7-4948-A58E-89F5D7614A47

Q36642014-5C70D340-8973-402C-9AD4-582B39731C33

Q36642014-5ECFACB0-0B6B-43DE-B016-E80C213BCBD3

P304

Q36642014-034A18C5-AA52-4119-8B3A-53D70A759D09

P31

Q36642014-010C967B-34F4-4C11-BCDE-8C691D4F832A

P356

Q36642014-F9F05461-22B0-445C-9654-3F5EBA9B391E

P407

Q36642014-C1ACF90B-D05B-4395-9C97-13BDCAD293E9

P433

Q36642014-8322AF75-4E6C-4334-ACBA-07F5EDB41347

P478

Q36642014-D8FD48B5-8EDF-46EE-8788-CF66541F7840

P577

Q36642014-3F95B75A-C537-49D1-9323-4D711311D4B4

P698

Q36642014-F2229698-7DF6-4CCC-B076-AD1900054A18

P932

Q36642014-D6C310EE-3A60-44D3-8A83-C43BF668532D

P356

STROKEAHA.112.675942

P1433

P1476

Amino terminal pro-B-type natr ...... oice of antithrombotic therapy

@en

P2093

Christopher R deFilippi

http://www.w3.org/2001/XMLSchema#string

David L Tirschwell

http://www.w3.org/2001/XMLSchema#string

J P Mohr

http://www.w3.org/2001/XMLSchema#string

John L P Thompson

http://www.w3.org/2001/XMLSchema#string

Mitchell S V Elkind

http://www.w3.org/2001/XMLSchema#string

Rebecca Gross

http://www.w3.org/2001/XMLSchema#string

Richard A Kronmal

http://www.w3.org/2001/XMLSchema#string

Richard Buchsbaum

http://www.w3.org/2001/XMLSchema#string

Robert H Christenson

http://www.w3.org/2001/XMLSchema#string

Robin L Brey

http://www.w3.org/2001/XMLSchema#string

P2860

The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke

Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke

Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing.

N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.

Natriuretic peptides and mortality after stroke.

Brain natriuretic peptide predicts functional outcome in ischemic stroke

Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine

Warfarin and aspirin in patients with heart failure and sinus rhythm.

P304

714-719

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.112.675942

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23339958

http://www.w3.org/2001/XMLSchema#string

P932

3583375

http://www.w3.org/2001/XMLSchema#string